Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Axitinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 453,498Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ocular Therapeutix Accelerated Timelines For SOL-1 Trial In Wet AMD
    Ocular Therapeutix Accelerated Timelines For SOL-1 Trial In Wet AMD

    15 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/15/2963077/0/en/Ocular-Therapeutix-Announces-Accelerated-Timelines-for-SOL-1-Registrational-Trial-of-AXPAXLI-in-Wet-AMD.html

    GLOBENEWSWIRE
    15 Oct 2024
    Share Share
    Clearside's CLS-AX excels in phase 2b trial, set for phase 3
    Clearside's CLS-AX excels in phase 2b trial, set for phase 3

    10 Oct 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/clearside-eye-disease-candidate-aces-exam-pursuit-roches-vabysmo-and-regeneron-and-bayers

    FIERCE PHARMA
    10 Oct 2024
    Share Share
    Ocular Therapeutix To Present At UBS Ophthalmology Day 2024
    Ocular Therapeutix To Present At UBS Ophthalmology Day 2024

    25 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/25/2952853/0/en/Ocular-Therapeutix-to-Present-at-the-UBS-Virtual-Ophthalmology-Day-2024.html

    GLOBENEWSWIRE
    25 Sep 2024
    Share Share
    Ocular Therapeutix Reports Inducement Grant
    Ocular Therapeutix Reports Inducement Grant

    12 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/12/2945588/0/en/Ocular-Therapeutix-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    12 Sep 2024
    Share Share
    Ocular Therapeutix™ to Present at September Retina Meetings
    Ocular Therapeutix™ to Present at September Retina Meetings

    05 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/05/2941241/0/en/Ocular-Therapeutix-to-Present-at-September-Retina-Meetings.html

    GLOBENEWSWIRE
    05 Sep 2024
    Share Share
    Ocular Therapeutix™ to Present at Two Investor Conferences
    Ocular Therapeutix™ to Present at Two Investor Conferences

    04 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/04/2940388/0/en/Ocular-Therapeutix-to-Present-at-Two-Investor-Conferences-in-September.html

    GLOBENEWSWIRE
    04 Sep 2024
    Share Share